Post-earnings recap
Reported
Tue, Nov 4, 2014
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a wider-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue figures and guidance may leave investors uncertain about the company's immediate future. The stock's reaction indicates a cautious sentiment among investors following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.31 | N/A | +4.62% |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to their clinical programs while acknowledging ongoing challenges. They emphasized their focus on future developments.
We are focused on advancing our clinical programs despite the challenges.
Our team remains committed to delivering results in the coming quarters.